Rowland, SVP at Ani Pharmaceuticals, sells $426k in stock

Published 14/08/2025, 23:00
Rowland, SVP at Ani Pharmaceuticals, sells $426k in stock

Thomas Andrew Rowland, SVP, HEAD - ESTABLISHED BRANDS at ANI Pharmaceuticals Inc (NASDAQ:ANIP), sold 4,975 shares of common stock on August 12, 2025, for approximately $426,407. The shares were sold in multiple transactions at prices ranging from $85.52 to $86.22. The sale comes as ANIP trades near its 52-week high of $90.23, with the stock showing remarkable strength, gaining over 30% in the past week alone. According to InvestingPro analysis, technical indicators suggest the stock is currently in overbought territory.

Following the transaction, Rowland directly owns 40,794 shares of ANI Pharmaceuticals Inc. common stock, which includes 304 shares acquired under the company’s Employee Stock Purchase Plan. With ANIP’s market capitalization now at $1.81 billion and an overall Financial Health score rated as GREAT by InvestingPro, investors can access comprehensive insider trading patterns and 15+ additional ProTips through the platform’s detailed research reports.

In other recent news, ANI Pharmaceuticals reported robust financial results for the second quarter of 2025, surpassing market expectations. The company achieved an adjusted non-GAAP earnings per share of $1.80, exceeding the FactSet consensus estimate of $1.41, and reported revenue of $211.4 million, which was above the anticipated $187.34 million. This strong performance led ANI Pharmaceuticals to raise its guidance for revenue, adjusted EBITDA, and EPS. The Cortrophin Gel product line was a significant contributor to this growth, with revenue reaching $81.6 million in Q2, marking a 66% year-over-year increase and a 54% sequential rise from the previous quarter. Following these results, Truist Securities raised its price target for ANI Pharmaceuticals to $77, maintaining a Hold rating. Similarly, H.C. Wainwright increased its price target to $93, while keeping a Buy rating on the stock. These developments indicate a positive outlook from analysts regarding the company’s future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.